HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Parenteral irons versus transfused red blood cells for treatment of anemia during canine experimental bacterial pneumonia.

AbstractBACKGROUND:
No studies have been performed comparing intravenous (IV) iron with transfused red blood cells (RBCs) for treating anemia during infection. In a previous report, transfused older RBCs increased free iron release and mortality in infected animals when compared to fresher cells. We hypothesized that treating anemia during infection with transfused fresh RBCs, with minimal free iron release, would prove superior to IV iron therapy.
STUDY DESIGN AND METHODS:
Purpose-bred beagles (n = 42) with experimental Staphylococcus aureus pneumonia rendered anemic were randomized to be transfused RBCs stored for 7 days or one of two IV iron preparations (7 mg/kg), iron sucrose, a widely used preparation, or ferumoxytol, a newer formulation that blunts circulating iron levels.
RESULTS:
Both irons increased the alveolar-arterial oxygen gradient at 24 to 48 hours (p = 0.02-0.001), worsened shock at 16 hours (p = 0.02-0.003, respectively), and reduced survival (transfusion 56%; iron sucrose 8%, p = 0.01; ferumoxytol 9%, p = 0.04). Compared to fresh RBC transfusion, plasma iron measured by non-transferrin-bound iron levels increased with iron sucrose at 7, 10, 13, 16, 24, and 48 hours (p = 0.04 to p < 0.0001) and ferumoxytol at 7, 24, and 48 hours (p = 0.04 to p = 0.004). No significant differences in cardiac filling pressures or performance, hemoglobin (Hb), or cell-free Hb were observed.
CONCLUSIONS:
During canine experimental bacterial pneumonia, treatment of mild anemia with IV iron significantly increased free iron levels, shock, lung injury, and mortality compared to transfusion of fresh RBCs. This was true for iron preparations that do or do not blunt circulating free iron level elevations. These findings suggest that treatment of anemia with IV iron during infection should be undertaken with caution.
AuthorsDante A Suffredini, Wanying Xu, Junfeng Sun, Jesús Barea-Mendoza, Steven B Solomon, Samuel L Brashears, Andreas Perlegas, Daniel B Kim-Shapiro, Harvey G Klein, Charles Natanson, Irene Cortés-Puch
JournalTransfusion (Transfusion) Vol. 57 Issue 10 Pg. 2338-2347 (10 2017) ISSN: 1537-2995 [Electronic] United States
PMID28656646 (Publication Type: Comparative Study, Journal Article)
Copyright© 2017 AABB.
Chemical References
  • Ferric Compounds
  • Iron
  • Ferric Oxide, Saccharated
  • Glucaric Acid
  • Ferrosoferric Oxide
Topics
  • Anemia (complications, etiology, mortality, therapy)
  • Animals
  • Disease Models, Animal
  • Dogs
  • Erythrocyte Transfusion (standards)
  • Ferric Compounds (administration & dosage, therapeutic use)
  • Ferric Oxide, Saccharated
  • Ferrosoferric Oxide (administration & dosage, therapeutic use)
  • Glucaric Acid (administration & dosage, therapeutic use)
  • Iron (administration & dosage, adverse effects, therapeutic use)
  • Lung Injury
  • Mortality
  • Pneumonia, Bacterial (complications)
  • Pneumonia, Staphylococcal (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: